Agree with most of these. Putting aside medical devices and just looking at 'true bios', i.e. drug development, the FA and myriad of product development complexities is too complicated for anyone who doesn't have a deep knowledge of the field, so your average punter is completely in the dark. It follows then that you should let someone else do the work for you. Early stage bios which don't have sophisticated investor backing by a reputable life science VC/investor should be avoided in my view. Many make the mistake of classing a 'deal' with big pharma as an evaluation of your drug candidate, which isn't that hard to get. If someone who understands the science and the field isn't willing to put big $ on the table then why should you? Good examples of these are OPT and VLA.
- Forums
- ASX - Short Term Trading
- Short Term Trading Weekend Lounge: 5 - 7th August
Short Term Trading Weekend Lounge: 5 - 7th August, page-282
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online